In conversation with Atul Modi, Chairman and Managing Director, Prevest Denpro Ltd

In conversation with Atul Modi, Chairman and Managing Director, Prevest Denpro Ltd

Armaan Madhani
/ Categories: Trending, Interviews

Our expansion and modernisation of existing factory are progressing satisfactorily, expresses Atul Modi, Chairman and Managing Director, Prevest Denpro Ltd

What is your outlook on the global dental industry? Also, what are the emerging trends and opportunities? 

Before proceeding, I would like to give you an overview of the dental market. Some of the primary factors that have a positive influence on the growth of the dental industry include rising causes of oral diseases, increasing per capita income, rising awareness about oral health, and increasing government spending on dental health services. As per WHO data, 3.5 billion people globally are affected by oral diseases, which are predominantly caries of permanent teeth, periodontal disease & oral cancer, and therefore, the need for dental treatments is growing. Apart from dental diseases, there is a growing demand for cosmetic dentistry, which is another promising area of business for the dental industry. Therefore, the dental industry has a very bright future with steady and sustainable growth in the years to come. 

 

In 9MFY22, Prevest Denpro reported revenue and net profit of Rs 29.54 crore and Rs 9.10 crore, respectively. The net profit margin stood at an impressive 30.83 per cent. During this period, domestic and export businesses witnessed robust growth of 84 per cent & 42 per cent, respectively on a YoY basis. What factors have contributed the most to help you outperform? 

At Prevest Denpro, we believe that “when the times get tougher, the tough get going”. The same belief reflects in our performance over these tough times of the COVID-19 pandemic. Even in these tough times, the vision and performance of our management team have been excellent. Our focus on the production & marketing of value-added products and expanding business in more countries has resulted in an excellent performance. With aggressive marketing efforts and participation in international dental trade fairs, the popularity of our products is growing in the international market, which is also instrumental in the growth of our business as well as excellent performance.  

 

Can you throw some light on the products that you have launched in 9MFY22? Also, discuss some of the new product launches that are in the pipeline for FY23. 

We have introduced new endodontic treatment materials, caries prevention & treatment products during 9MFY22 while for FY23, we are going to launch an innovative range of oral hygiene and oral care products. We are also going to launch bone-grafting materials and periodontal dressings, which have a wide international market. 

 

What are your Capex plans for FY23? 

Our expansion and modernisation of existing factory are progressing satisfactorily. The procurement of plant & machinery is being processed, and other required infrastructural requirements are being implemented. Besides, our research & development (R&D) centre will be operational by Q1FY23. 

 

Presently, what are your top three strategic priorities? 

At this time, we are focussing on making our R&D centre operational so that, we can expedite the development of new products. Our next priority is to make our new manufacturing facility operational during Q2FY23 along with augmenting the manufacturing capacity of our existing factory with the installation of new high-tech equipment. Lastly, we have planned an aggressive marketing strategy for business growth. With the implementation of the expansion of our existing business & diversification into oral hygiene, oral care, and biomaterials project, we believe that we will be able to cater to the dental professionals with a much larger product portfolio, covering all major segments of dentistry. We are confident that with our own state-of-the-art research centre, collaboration with various dental institutions, eminent advisory board, and newer innovative high-quality products to be introduced in the new future, our company is well on track to achieve its transformational goal. 

Previous Article Stocks below Rs 100: Only buyers seen in these scrips on April 18
Next Article As the week opened on a negative note, these stocks witnessed a massive surge!
Rate this article:
3.8

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR